Serena Meraviglia

TL;DR: Zoledronate + IL-2 represents a novel, safe, and feasible approach to induce immunologic and clinical responses in patients with metastatic carcinomas, potentially providing a substantially increased window for specific approaches to be administered.

TL;DR: The data emphasize the strong linkage of Vγ9Vδ2 T cell status to reduced carcinoma progression, and suggest that zoledronate plus low‐dose IL‐2 offers a novel, safe and feasible approach to enhance this in a subset of treatment‐refractory patients with advanced breast cancer.

TL;DR: The findings delineate a previously unknown subset of human IL-17(+) Vγ9Vδ2 T lymphocytes implicated in the pathophysiology of inflammatory responses during bacterial infections.

TL;DR: It is concluded that intentional activation of Vγ9Vδ2 T cells by zoledronate may substantially increase antitumor activities and represent a novel strategy for colon cancer immunotherapy.

TL;DR: Bisphosphonates are analogues of endogenous pyrophosphate in which a carbon atom replaces the central atom of oxygen and this carbon substitution makes these compounds resistant to hydrolysis and allows 2 additional chains of variable structure.